Apis | Vespula | |
---|---|---|
Number | 81 | 65 |
Age (years)* | 42.33 ± 12.58 | 39.2 ± 13.06 |
[46 (18–70)] | [38 (17–70)] | |
Gender | ||
Female, no (%) | 34 (42 %) | 33 (51 %) |
Male, no (%) | 47 (58 %) | 32 (49 %) |
Severity of systemic reactions (%) | ||
Grade I | 9 (11.1) | 5 (7.7) |
Grade II | 21 (26) | 25 (38.5) |
Grade III | 24 (29.6) | 15 (23) |
Grade IV | 27 (33.3) | 20 (30.8) |
Patient groups for cross-sectional validation | ||
New diagnosis | 18 (22.2) | 23(35.4) |
Recently started (up-dosing) VIT | 30 (37) | 18 (27.7) |
Receiving on maintenance VIT | 22 (27.2) | 16 (24.6) |
Stopped VIT | 11 (13.6) | 8 (12.3) |